Opinion ID: 209997
Heading Depth: 3
Heading Rank: 3

Heading: Caraco's Injury Is Redressible by a Favorable Judgment

Text: Finally, Caraco's injury-in-fact is redressible by a declaratory judgment that the '941 patent is not infringed. [10] A favorable judgment in this case would clear the path to FDA approval that Forest's actions would otherwise deny Caraconamely, using the court-judgment trigger of 21 U.S.C. § 355(j)(5)(B)(iv)(II) (2000) to activate Ivax's exclusivity period. If Caraco obtains a favorable judgment that the drug described in its ANDA does not infringe Forest's '941 patent, then it will only need a judgment of invalidity or noninfringement on Forest's '712 patent in order to activate Ivax's exclusivity period and obtain FDA approval as swiftly as possible. Thus, a favorable judgment in this action would eliminate the potential for the '941 patent to exclude Caraco from the drug market. [11]